Thinking of joining a study?

Register your interest

NCT04547179 | Unknown status | Migraine


Medicinal vs. Orthotic Comparison for Migraine Prevention: A Double-Blind Study
Sponsor:

Manhattan Beach Orthodontics

Information provided by (Responsible Party):

Dr. Sunitha Bhardiya

Brief Summary:

To understand the impacts of using a fixed orthotic facial exercise appliance (BLAfit®) for migraine reduction, as compared to medication (fremanezumab-vfrm) and control.

Condition or disease

Migraine

Intervention/treatment

Fremanezumab-Vfrm

BLAfit®

Saline

Phase

Not Applicable

Detailed Description:

The investigators will be studying the impacts of using an orthotic facial exercise device (BLAfit®) in the prevention of migraines for those who suffer from roughly 10-15 migraines per month. In order to test the efficacy of this device and its exercise routine, investigators will have one arm of our study receive the BLAfit® device and perform the exercises for one minute daily for three months. In Arm #2, there will be another treatment: Ajovy® (fremanezumab-vfrm) injections- which is a known and commonly practiced clinical prevention treatment for migraine patients. Patients in this arm will receive three injections of Ajovy, which is will be meant to last 3 months. In addition, investigators will have a placebo group that will receive three saline injections, which are meant to mimic the three Ajovy® injections. Arms #2 and #3 of this study will be conducted in a double-blind fashion, as both the clinician providing the injections and the patients receiving the injections will not know if the injecting substance is Ajovy or saline, so as to minimize bias. All patients in all three months will log their number and pain level of their migraines each day for three months. Upon conclusion, they will meet with our in-house neurologist (Principal Investigator & Sponsor) for a final in-person evaluation and questionnaire. Results from the three groups will then be analyzed.}}

Study Type : Interventional
Estimated Enrollment : 80 participants
Masking : Double
Primary Purpose : Prevention
Official Title : Medicinal vs. Orthotic Comparison for Migraine Prevention: A Double-Blind Study
Actual Study Start Date : February 1, 2021
Estimated Primary Completion Date : April 15, 2021
Estimated Study Completion Date : December 1, 2021
Arm Intervention/treatment

Experimental: BLAfit® usage

In this arm, subjects will used the fixed orthotic device called BLAfit® for one minute of facial exercise a day for three months.

Device: BLAfit®

Experimental: fremanezumab-vfrm

Subjects in this arm will receive three Ajovy® (fremanezumab-vfrm) injections at the start of month 2. This will be conducted in a double-blind fashion, as both the clinician providing the injection, and the subject, will not know if the injection is actually Ajovy® or just saline.

Drug: Fremanezumab-Vfrm

Placebo Comparator: Saline injection

This is a placebo that is used to counter Arm #2- the Ajovy® injections. Subjects in this arm will receive three saline injections at the start of month 2 that will mimic the Ajovy® injections. This will be conducted in a double-blind fashion, as both the clinician providing the injection, and the subject, will not know if the injection is actually Ajovy® or just saline.

Other: Saline

Ages Eligible for Study: 18 Years to 55 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Accepts Healthy Volunteers
Criteria
Inclusion Criteria
  • Those eligible to participate must be between the ages of 18 to 55 years.
  • The individual must experience at least 2 migraines per week.
  • They must be capable of visiting the medical facility in Manhattan Beach, California where the in-person screening and final evaluation will be conducted (following COVID-19 public health guidelines).
  • They must be able to communicate with the study team via any teleconferencing service such as Zoom, Google Hangouts, or FaceTime.
Exclusion Criteria
  • Patients must not have any intracranial pathology, neurological or psychological conditions, epilepsy, cancer, any history of chemotherapy, hospitalized for depression, psychiatric conditions, seizures, or tumors.
  • Patients cannot have taken Botox® for migraine treatments.
  • Patients cannot have had a history of head or neck surgery.
  • Patients cannot be taking: propranolol, amitriptyline, flunarizine, topiramate, combination, galcanezumab-gnlm, fremanezumab-vfrm, or erenumab-aooe.
  • Patients must not be deemed a vulnerable subject (including but not limited to: children, prisoners, pregnant women, mentally disabled persons).

Medicinal vs. Orthotic Comparison for Migraine Prevention: A Double-Blind Study

Location Details


Please Choose a site



Medicinal vs. Orthotic Comparison for Migraine Prevention: A Double-Blind Study

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


Not yet recruiting

United States, California

Manhattan Beach Orthodontics

Manhattan Beach, California, United States, 90266

Loading...